OCGNOcugen, Inc.vs its industry peers
A metric-by-metric comparison of Ocugen, Inc. against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OCGNThis | $258M#8 | — | — | 58.4x#8 | 8.8%#5 | -25.9%#8 | -1425.7%#7 | — | — | — | -50.2%#11 | — |
| XFOR | $313M#1 | 2.2x#2 | 2.0x#10 | 8.9x#4 | 1273.2%#2 | -111.5%#12 | -247.4%#4 | -50.9%#9 | -582.0%#4 | — | -22.8%#8 | — |
| SCTX | $308M#2 | — | — | — | — | — | — | — | — | — | — | — |
| AGEN | $301M#3 | 2.2x#3 | — | 2.6x#2 | 10.4%#4 | 98.7%#2 | -17.7%#3 | — | — | — | 68.5%#2 | — |
| EIKN | $300M#4 | — | 0.6x#2 | — | — | — | — | 0.0%#2 | — | — | — | — |
| SABS | $285M#5 | 13.0x#5 | 1.3x#6 | — | -100.0%#9 | 138.9%#1 | — | 6.2%#1 | — | — | — | — |
| IPSC | $274M#6 | — | 1.2x#5 | 2.5x#1 | 1556.8%#1 | 92.4%#3 | -15.8%#2 | -4.1%#3 | -9.3%#1 | — | 152.6%#1 | — |
| LCTX | $258M#7 | — | 4.2x#12 | 17.7x#6 | 53.2%#3 | -241.4%#13 | -251.6%#5 | -104.3%#12 | — | — | -47.8%#10 | — |
| LXEO | $257M#9 | — | 1.1x#3 | 393.3x#9 | — | -1.7%#5 | -16706.0%#9 | -42.5%#8 | — | — | -65.3%#13 | — |
| FATE | $245M#10 | — | 1.6x#8 | 36.9x#7 | -51.2%#7 | 26.8%#4 | -2222.4%#8 | -88.8%#11 | -102.3%#3 | — | 62.9%#3 | — |
| CABA | $242M#11 | — | 1.2x#4 | — | — | -44.9%#10 | — | -79.7%#10 | — | — | -52.3%#12 | — |
| ALEC | $230M#12 | — | — | 10.9x#5 | -79.1%#8 | -20.2%#7 | -741.3%#6 | — | — | — | 42.1%#4 | — |
| PALI | $216M#13 | 1.9x#1 | 1.8x#9 | — | — | -16.2%#6 | — | -13.8%#5 | — | — | -37.8%#9 | — |
| PLX | $209M#14 | 11.3x#4 | 2.9x#11 | 4.0x#3 | -1.2%#6 | -325.2%#14 | -10.4%#1 | -9.2%#4 | -12.3%#2 | 3#1 | 9.3%#6 | — |
| IKT | $208M#15 | — | 1.4x#7 | — | -100.0%#9 | -75.4%#11 | — | -31.5%#7 | — | — | -8.0%#7 | — |
| ARTV | $206M#16 | — | 0.6x#1 | — | -100.0%#9 | -28.3%#9 | — | -24.1%#6 | — | — | 12.0%#5 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice